Suitable for use in pharmacokinetic (PK) assay. Other applications have not been tested but use in such assays should not necessarily be excluded.
Recommended Working Concentration: 0.01-0.1 μg/ml
Summary
Specifications
Antibody Isotype
IgG
Clone
58G7
Immunogen
Nivolumab
Conjugate
Unconjugated
Applications
Application Notes
Suitable for use in pharmacokinetic (PK) assay. Other applications have not been tested but use in such assays should not necessarily be excluded. Recommended Working Concentration: 0.01-0.1 μg/ml
General Notes
Suitable for use in pharmacokinetic (PK) assay. Other applications have not been tested but use in such assays should not necessarily be excluded. Nivolumab (Opdivo) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of patients with unresectable or metastatic melanoma. Nivolumab binds to the human cell surface receptor PD-1 (Programmed Cell Death Protein 1) and blocks its interaction with PD-L1, resulting in the activation of T-cell-mediated immune responses against tumor cells.
Target
Alternative Names
Rabbit monoclonal antibody to Opdivo; MDX-1106; Nivolumab
Citations
Publication ()
Have you cited CABT-ZB218 in a publication? Let us know and earn a reward for your research.
My Review for Rabbit Anti-Nivolumab monoclonal antibody, clone 58G7
Creative Diagnostics products are for RESEARCH USE ONLY, please make sure your review is research based.
Required fields are marked with *
Terms and conditions:
We will select high-quality review customers and offer a $30 coupon for your next purchase.
All product reviews must be submitted in the English language.
Creative Diagnostics will not share any personal information of applicants, and all information will be treated with strict confidentiality and will not be sold or disclosed to a third party.
COA
Publication 
Loading ......
